Tag - Crl

Small-cap stocks remained sharply lower into mid-session, pressured by fresh worries about the health of the banking sector as we enter into earnings season and by dreadful retail sales numbers this morning.  Some of today’s small-cap gainers were LaBranche (NYSE:LAB), Vahli, Inc. (NYSE:VHI) and Panhandle Oil and Gas (NYSE:PHX).

Other Market Watch highlights today included:

• The Energy Select Sector SPDR Fund was off 4.5% at midday.  
• Crude oil tumbled amid the sell-off in stocks; energy shares were dueling with financials for the biggest downside market hit so far today.  
• Bank stocks took a hit in European trading ahead of today’s opening and those concerns continued to play out during the U.S. session.  
• Financials, commodities, retailers and manufacturers are all taking a hit, but the slide in bank stocks is a major spot of bother.

Small Cap Gainers:

• Goldman Sachs upgrades LaBranche; shares rise 16%. See (NYSE:LAB). 
• Valhi, Inc. up 9% after announcing issuance of final low-level radioactive waste disposal license. See (NYSE:VHI).  
• Panhandle Oil and Gas up 6% after declaring a dividend last week. See (NYSE:PHX).   • Charles River schedules 2008 earnings and 2009 guidance release for Feb. 9; shares rise over 5%. See (NYSE:CRL).  

Small Cap Losers:

• Allis-Chalmers Energy slides 16% as energy stocks are feeling the heat today. See (NYSE:ALY).  
• Cliffs Natural Resources shares drop over 15% on deferral. See (NYSE:CLF).
• National Financial Partners Corp. slides 14% as financials nosedive today. See (NYSE:NFP).  
• North American Energy Partners down over 12% on light volume, pulled down by the slump in energy stocks. See (NYSE:NOA).  

Investing in pharmaceutical companies can be a risky business where investors essentially bet on whether clinical trials will pass with flying colors, which many times isn’t the case. Many drug companies have now adopted the method of “outsourcing” clinical trial testing to firms such as Life Sciences Research, Inc. (NYSE:LSR), to assuage risk that could directly affect financial results.
 
The outsourcing of drug testing is becoming big business: it’s currently estimated that 25% to 30% of pre- and non-clinical testing is outsourced, and industry analysts such as Hamed Khorsand with BWS Financial believe that this percentage, as well as the absolute dollars that go toward outsourcing, will continue to grow.

Life Sciences, which has an estimated annual testing capacity of over $300 million, is in the business of teaming up with clients for Phase 1 clinical trials to independently verify results. The company is the largest provider of pre-clinical efficacy testing in the United Kingdom and Europe, and is globally one of the “big three” that include Covance (NYSE:CVD) and Charles River Labs (NYSE:CRL).

On top of assessing whether products meet regulatory and commercial requirements for human consumption, Life Sciences also tests the effect of compounds on the environment and assesses the safety and efficacy of veterinary products, though 85% of the small cap’s customers are pharmaceutical companies.

The company is beginning to catch Wall Street’s attention: Life Sciences has brought its operating margin back to the 15% to 17% range, with aggressive growth that has yet to reach a ceiling. According to Khorsand, the small cap is sitting on an approximate 26% growth capacity.

The staple of Life Sciences’ growth is a reflection of growth in the pharmaceutical industry as a whole. As more and more potential drugs are tested for market, the need for independent research jumps. Will there be new drugs for the treatment of depression, cancer, weight control, blood pressure and other ailments? Count on it. In order for the pharmaceutical industry to achieve its targeted margin growth, the industry will need to bring an even greater number of therapies to . . .